α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of aggregates (Lewy bodies) in neurons. alpha-Synuclein is the major protein in Lewy bodies and rare mutations in alpha-synuclein cause early-onset PD. Consequently, alpha-synuclein is implicated in the pathogenesis of PD. Here, we have investigated the degradation pathways of alpha-synuclein, using a stable inducible PC12 cell model, where the expression of exogenous human wild-type, A30P, or A53T alpha-synuclein can be switched on and off. We have used a panel of inhibitors/stimulators of autophagy and proteasome function and followed alpha-synuclein degradation in these cells. We found that not only is alpha-synuclein degraded by the proteasome, but it is also degraded by autophagy. A role for autophagy was further supported by the presence of alpha-synuclein in organelles with the ultrastructural features of autophagic vesicles. Since rapamycin, a stimulator of autophagy, increased clearance of alpha-synuclein, it merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, mutant forms of synuclein and oligomers are dependent on the autophagy–lysosome pathway for their clearance4–6.”
From Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice (2018) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies suggest that α-synuclein is degraded by macroautophagy, chaperone-mediated autophagy, and the proteasome20–23.”
From Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Macroautophagy is a key pathway for the clearance of aggregate-prone cytosolic proteins.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
In the citing paper
“Early evidence suggested roles for CMA and macroautophagy in degrading SNCA/α‐synuclein (Webb et al, 2003; Cuervo et al, 2004).”
From Autophagy in major human diseases (2021) · cites this paper as Webb et al, 2003
In the citing paper
“We previously showed that EGFP-HDQ74 is cleared by autophagy.”
From Lithium induces autophagy by inhibiting inositol monophosphatase (2005) · cites this paper as Webb et al., 2003
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Conway, K. A., Harper, J. D., & Lansbury, P. T. (1998) · Nature Medicine · doi:10.1038/3311 · Cited by 1,499
Research works printed but not linked: 2
- Furlong, R. A., Narain, Y., Rankin, J., Wyttenbach, A., and Rubinsztein, D. C. (2000) Biochem. J. 346, 577-581 · DOI · Paper page
- Biederbick, A., Kern, H. F., and Elsasser, H. P. (1995) Eur. J. Cell Biol. 66, 3-14
Cited by
Items 401–500 of 1,001
Jang, W., Kim, H., Li, H., Jo, K. D., Lee, M. K., Song, S. H., & Yang, H. O. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.081 · Cited by 109
Mitophagy in neurodegenerative diseases
Rodolfo, C., Campello, S., & Cecconi, F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.004 · Cited by 100
“…pars compacta (SNpc), and by the formation of intra-neuronal protein aggregates of a-synuclein, called Lewy body, which are cleared by autophagy (Webb et al., 2003); ii) Alzheimer's disease (AD) is characterised by brain atrophy, associated with both neuronal and synaptic loss, accumulation of…”
BackgroundAutophagy regulates exosomal release of prions in neuronal cells
Abdulrahman, B. A., Abdelaziz, D. H., & Schatzl, H. M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000713 · Cited by 104
“The clearance of aggregation-prone proteins, such as mutant huntingtin fragments or mutant forms of αsynuclein causing Huntington’s and Parkinson’s disease, respectively, can be mediated by autophagy [44,45].”
BackgroundExpanding Insights on the Involvement of Endoplasmic Reticulum Stress in Parkinson's Disease
Wang, H., & Takahashi, R. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.1524 · Cited by 102
Mitochondrial Quality Control and Dynamics in Parkinson's Disease
McCoy, M. K., & Cookson, M. R. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4019 · Cited by 101
“Furthermore, disease-associated mutations in a-synuclein allow the protein to interact more strongly with the LAMP2A receptor, but internalization of mutant protein into the lysosome is less efficient, which inhibits degradation of both a-synuclein and other CMA substrates (25).”
BackgroundButler, D., & Bahr, B. A. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.185 · Cited by 101
“Synaptic terminals are sensitive to oxidative insults, resulting in increased levels of active p53 in synapses where it causes mitochondrial perturbation increases calcium channel function (27) that can activate the calcium-dependent protease calpain upstream of p53.”
Kett, L. R., Stiller, B., Bernath, M. M., Tasset, I., Blesa, J., Jackson-Lewis, V., Chan, R. B., Zhou, B., Di Paolo, G., Przedborski, S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0632-14.2015 · Cited by 100
“In light of the previously described lysosomal degradation of -synuclein by both macroautophagy and CMA (Webb et al., 2003; Cuervo et al., 2004; Martinez-Vicente et al., 2008; Vogiatzi et al., 2008; Winslow et al., 2010; Ebrahimi-Fakhari et al., 2011; Xilouri et al., 2013) and of the disruption of this process in othe…”
BackgroundInfluentialChaperone-mediated autophagy in aging and neurodegeneration: Lessons from α-synuclein
Bandyopadhyay, U., & Cuervo, A. M. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.05.019 · Cited by 115
Wu, H., Chen, S., Al-Baadani, A., Xu, J., Wu, Q., Pan, K., Zhang, J., & Hong, Y. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8933-0 · Cited by 107
“importantly, macroautophagy serves as a route for intracellular α-synuclein degradation to ameliorate the neurodegenerative pathology in PD models [89, 90].”
BackgroundA new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts
Carmassi, C., Del Grande, C., Gesi, C., Musetti, L., & Dell'Osso, L. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s106479 · Cited by 97
Bustamante, H. A., González, A. E., Cerda-Troncoso, C., Shaughnessy, R., Otth, C., Soza, A., & Burgos, P. V. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00126 · Cited by 100
“As an example, these two pathways share common substrates, such as the case of the aggregate-prone protein α-synuclein, the major component of Lewy bodies in Parkinson Disease (PD), which is a substrate of the UPS and ALP (Bennett et al., 1999; Webb et al., 2003).”
BackgroundTherapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease
Jasutkar, H. G., Oh, S. E., & Mouradian, M. M. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000133 · Cited by 111
“Reducing a -Syn phosphorylation pharmacologically through activating PP2A is particularly pertinent mechanistically considering that in PD and DLB brains, PP2A is demethylated, PME1 is upregulated, and the methylating enzyme leucine carboxyl methyltransferase is downregulated (Park et al., 2016).”
BackgroundInfluentialvan Dijk, K. D., Persichetti, E., Chiasserini, D., Eusebi, P., Beccari, T., Calabresi, P., Berendse, H. W., Parnetti, L., & van de Berg, W. D. J. (2013) · Movement Disorders · doi:10.1002/mds.25495 · Cited by 101
Autophagy in Neurodegenerative Diseases and Metal Neurotoxicity
Zhang, Z., Miah, M. R., Culbreth, M. E., & Aschner, M. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1844-x · Cited by 107
“a-synuclein can be degraded by macroautophagy, CMA, and the proteasome [12, 13].”
BackgroundAutophagic pathways in Parkinson disease and related disorders
Xilouri, M., & Stefanis, L. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001803 · Cited by 113
Therapeutic implication of autophagy in neurodegenerative diseases
Rahman, M. A., & Rhim, H. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.7.069 · Cited by 106
The TBC/RabGAP Armus Coordinates Rac1 and Rab7 Functions during Autophagy
Carroll, B., Mohd-Naim, N., Maximiano, F., Frasa, M. A., McCormack, J., Finelli, M., Thoresen, S. B., Perdios, L., Daigaku, R., Francis, R. E., et al. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.03.005 · Cited by 98
“Armus labeled mostly the outer membrane of autophagosomes, while a-synuclein, a mutant protein known to aggregate (Webb et al., 2003), formed small puncta in keratinocytes that were clearly distinct from Armus-induced vesicles (Figure S1B).”
BackgroundWang, P., Lazarus, B. D., Forsythe, M. E., Love, D. C., Krause, M. W., & Hanover, J. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205748109 · Cited by 99
Chang, C., Huang, H., Lee, H., Hung, K., Wu, R., & Lin, A. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00945.x · Cited by 98
Negative regulation of autophagy by UBA6-BIRC6–mediated ubiquitination of LC3
Jia, R., & Bonifacino, J. S. (2019) · eLife · doi:10.7554/elife.50034 · Cited by 107
Genes associated with Parkinson's disease: regulation of autophagy and beyond
Beilina, A., & Cookson, M. R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13266 · Cited by 93
PA700, the regulatory complex of the 26S proteasome, interferes with α‐synuclein assembly
Ghee, M., Melki, R., Michot, N., & Mallet, J. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04776.x · Cited by 96
Chen, L., Song, J., Lu, J., Yuan, Z., Liu, L., Durairajan, S. S. K., & Li, M. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9528-2 · Cited by 102
Fortun, J., Verrier, J. D., Go, J. C., Madorsky, I., Dunn, W. A., & Notterpek, L. M. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.018 · Cited by 103
ɑ‐Synuclein strains and the variable pathologies of synucleinopathies
Peelaerts, W., & Baekelandt, V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13595 · Cited by 105
Manzanza, N. D. O., Sedlackova, L., & Kalaria, R. N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690293 · Cited by 102
Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective
Yi, S., Wang, L., Wang, H., Ho, M. S.-C., & Zhang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314753 · Cited by 102
Wang, Z., Hu, W., Zhang, J.-L., Wu, X.-H., & Zhou, H.-J. (2012) · FEBS Open Bio · doi:10.1016/j.fob.2012.05.002 · Cited by 92
Proteasome activation delays aging in vitro and in vivo
Chondrogianni, N., Sakellari, M., Lefaki, M., Papaevgeniou, N., & Gonos, E. S. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.031 · Cited by 94
“The two mechanisms share a lot of common substrates for degradation [160–163], and they have a common recognition signal, namely the ubiquitin chains.”
BackgroundRelieving Autophagy and 4EBP1 from Rapamycin Resistance
Nyfeler, B., Bergman, P., Triantafellow, E., Wilson, C. J., Zhu, Y., Radetich, B., Finan, P. M., Klionsky, D. J., & Murphy, L. O. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05430-11 · Cited by 94
“Furthermore, autophagy activation by rapamycin clears aggregation-prone proteins such as mutant Huntingtin or -synuclein in cell culture (33, 44), and CCI-779 reduces the aggregate load in a mouse model of Huntington’s disease (34).”
BackgroundLoss of Parkin contributes to mitochondrial turnover and dopaminergic neuronal loss in aged mice
Noda, S., Sato, S., Fukuda, T., Tada, N., Uchiyama, Y., Tanaka, K., & Hattori, N. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104717 · Cited by 100
“The protein catabolic pathways that regulate synuclein degradation have been discussed by multiple authors (Ebrahimi-Fakhari et al., 2011; Rideout et al., 2004; Webb et al., 2003).”
BackgroundPromiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies
Limanaqi, F., Biagioni, F., Gambardella, S., Familiari, P., Frati, A., & Fornai, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083028 · Cited by 97
“Rapamycin, an autophagy inducer, remarkably increases α-syn clearance, suggesting that autophagy represents the major degradation pathway for synuclein [53].”
BackgroundDrobny, A., Huarcaya, S. P., Dobert, J. P., Kluge, A., Bunk, J., Schlothauer, T., & Zunke, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119243 · Cited by 105
LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?
Taylor, J. P., Mata, I. F., & Farrer, M. J. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.12.004 · Cited by 108
Synphilin-1 attenuates neuronal degeneration in the A53T -synuclein transgenic mouse model
Smith, W. W., Liu, Z. W., Liang, Y., Masuda, N., Swing, D. A., Jenkins, N. A., Copeland, N. G., Troncoso, J. C., Pletnikov, M. V., Dawson, T. M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq086 · Cited by 100
“Supporting this possibility is the finding that the autophagy activator, rapamycin, stimulates a-synuclein clearance (39,40).”
BackgroundAutophagy stimulation as a promising approach in treatment of neurodegenerative diseases
Pierzynowska, K., Gaffke, L., Cyske, Z., Puchalski, M., Rintz, E., Bartkowski, M., Osiadły, M., Pierzynowski, M., Mantej, J., Piotrowska, E., et al. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0214-6 · Cited by 88
“Studies on cellular models gave promising results, indicating a possibility to enhance degradation of proteins which cause different disorders, including mutant huntingtin (mHTT) (Ravikumar et al. 2002; Sarkar et al. 2008) and alpha-synuclein (Webb et al. 2003).”
BackgroundRecombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models
Huarcaya, S. P., Drobny, A., Marques, A. R. A., Spiezio, A. D., Dobert, J. P., Balta, D., Werner, C. D., Rizo, T., Gallwitz, L., Bub, S., et al. (2022) · Autophagy · doi:10.1080/15548627.2022.2045534 · Cited by 105
“Moreover, clearance of aggregated SNCA from the cytosol is mediated via macroautophagy [24,26,29].”
BackgroundLonskaya, I., Shekoyan, A. R., Hebron, M. L., Desforges, N., Algarzae, N. K., & Moussa, C. E.-H. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121141 · Cited by 91
Li, R., Lu, Y., Zhang, Q., Liu, W., Yang, R., Jiao, J., Liu, J., Gao, G., & Yang, H. (2021) · Autophagy · doi:10.1080/15548627.2021.1937897 · Cited by 97
“SNCA can be degraded by both ALP and the ubiquitin-proteasome system (UPS) [25,26]; therefore, the pathway of SNCA degradation was examined in greater detail.”
BackgroundMolecular pathogenesis of seipin/BSCL2‐related motor neuron diseases
Ito, D., & Suzuki, N. (2007) · Annals of Neurology · doi:10.1002/ana.21070 · Cited by 90
Scheper, W., & Hoozemans, J. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787458506 · Cited by 90
“-Synuclein is also degraded by autophagy [103] and pathogenic -synuclein mutants inhibit the degradation of -synuclein by the chaperone-mediated autophagy pathway [104].”
BackgroundDavies, S. E. W., Hallett, P. J., Moens, T. G., Smith, G. A., Mangano, E. N., Kim, H. T., Goldberg, A. L., Liu, J., Isacson, O., & Tofaris, G. K. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.12.011 · Cited by 98
“In addition, it is well established that αsynuclein is degraded by multiple pathways (Tofaris et al., 2001, 2011; Webb et al., 2003) which may exhibit variable functional redundancy in neuronal versus non-neuronal tissues.”
BackgroundMolecular Mechanisms in Exercise-Induced Cardioprotection
Golbidi, S., & Laher, I. (2011) · Cardiology Research and Practice · doi:10.4061/2011/972807 · Cited by 104
“Decreased autophagy can promote the development of cancer [157] and neurodegenerative conditions including Alzheimer’s [158] and Parkinson’s disease [159].”
BackgroundIGF-1 receptor antagonism inhibits autophagy
Renna, M., Bento, C. F., Fleming, A., Menzies, F. M., Siddiqi, F. H., Ravikumar, B., Puri, C., Garcia-Arencibia, M., Sadiq, O., Corrochano, S., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt300 · Cited by 89
Self-citationThe emerging role of autophagy in Parkinson's disease
Cheung, Z. H., & Ip, N. Y. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-29 · Cited by 88
“One of the first evidence in support of an important role of autophagy in PD came from the demonstration that alpha-synuclein is degraded by macroautophagy and CMA [19-21].”
BackgroundJang, W., Kim, H., Li, H., Jo, K. D., Lee, M. K., & Yang, H. O. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9316-x · Cited by 92
Luan, Y., Ren, X., Zheng, W., Zeng, Z., Guo, Y., Hou, Z., Guo, W. M., Chen, X., Li, F. Y., & Chen, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00301 · Cited by 96
“…analysis coupled with previous findings of activation of UPS by A2AR agonists (Chiang et al., 2009) (not antagonist such as caffeine) and preferentially clearance of aggregated α-Syn by autophagy (Webb et al., 2003), we have mainly focused on the analysis of autophagy pathway in our study.”
Chapter 5 Autophagic Clearance of Aggregate‐Prone Proteins Associated with Neurodegeneration
Sarkar, S., Ravikumar, B., & Rubinsztein, D. C. (2009) · Methods in Enzymology · doi:10.1016/s0076-6879(08)04005-6 · Cited by 79
Self-citationProtective effects of Angelica sinensis extract on amyloid β-peptide-induced neurotoxicity
Huang, S., Lin, C., & Chiang, B. (2008) · Phytomedicine · doi:10.1016/j.phymed.2008.02.022 · Cited by 92
“However, autophagic cell death of neurons has been reported in patients with Huntington disease, PD, and AD (Anglade et al., 1997; Webb et al., 2003; Cataldo et al., 1994).”
Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery
Arotçarena, M.-L., Teil, M., & Dehay, B. (2019) · Cells · doi:10.3390/cells8060565 · Cited by 97
“In PC12 cells that overexpress WT or mutated forms of α-syn (A30P, A53T), Webb and colleagues demonstrated that the induction of MA using the mTOR inhibitor rapamycin leads to an increased clearance of both WT and mutated forms of α-syn [63].”
BackgroundShen, Q., Jv, X.-H., Ma, X., Li, C., Liu, L., Jia, W., Qu, L., Chen, L., & Xie, J. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01153-z · Cited by 99
“The inducible PC12 cell line overexpressing α -synuclein (A53T) was a generous gift from Prof. David C. Rubinsztein at Cambridge University [11].”
Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD
Esteves, A. R., Arduíno, D. M., Silva, D. F. F., Oliveira, C. R., & Cardoso, S. M. (2011) · Parkinson's Disease · doi:10.4061/2011/693761 · Cited by 90
“Rapamycin has been shown to degrade all forms of alpha-syn in a stable inducible PC12 cell model [251].”
van Veen, S., Sørensen, D. M., Holemans, T., Holen, H. W., Palmgren, M. G., & Vangheluwe, P. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00048 · Cited by 88
“…control the delivery of α - synuclein to the lysosomes by regulating different autophagy pathways such as macro-autophagy (Dehay et al., 2012b; Usenovic et al., 2012a) and chaperone-mediated autophagy, two autophagic routes that control α -synuclein turnover (Webb et al., 2003; Mak et al., 2010).”
BackgroundInfluentialOxidation and nitration of α-synuclein and their implications in neurodegenerative diseases
Chavarría, C., & Souza, J. M. (2013) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.02.009 · Cited by 88
Processing of Optineurin in Neuronal Cells
Shen, X., Ying, H., Qiu, Y., Park, J.-S., Shyam, R., Chi, Z.-L., Iwata, T., & Yue, B. Y. J. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175810 · Cited by 88
The effects of oxidative stress on parkin and other E3 ligases
LaVoie, M. J., Cortese, G. P., Ostaszewski, B. L., & Schlossmacher, M. G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04911.x · Cited by 89
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
“Huntingtin [96, 97], -synuclein [98] and ataxin-3 [99, 100] have all been described as substrates of the proteasome as well as autophagy.”
BackgroundProteostasis Disturbances and Inflammation in Neurodegenerative Diseases
Sonninen, T.-M., Goldsteins, G., Laham-Karam, N., Koıstınaho, J., & Lehtonen, Š. (2020) · Cells · doi:10.3390/cells9102183 · Cited by 100
“While both UP S and autophagy can clear α -SYN, the main pathway for its degradation appears to be lysosomal [50,51]. α -SYN can be degraded by macroautophagy and chaperone-mediated autophagy (CMA) depending on the structure of the aggregate and possible mutations in genes associated with PD [52] .”
BackgroundJenner, P. G., Mori, A., Aradi, S. D., & Hauser, R. A. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1880896 · Cited by 96
Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration
Wales, P., Pinho, R., Lázaro, D. F., & Outeiro, T. F. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130216 · Cited by 86
“The first report of differential degradative pathways for ASYN suggested that ASYN may be degraded by both proteasomal and autophagic pathways [211].”
Puyal, J., Ginet, V., Grishchuk, Y., Truttmann, A. C., & Clarke, P. G. H. (2012) · The Neuroscientist · doi:10.1177/1073858411404948 · Cited by 84
LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
O’Hara, D. M., Pawar, G., Kalia, S. K., & Kalia, L. V. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00577 · Cited by 85
“…activity of LRRK2, as discussed below (Figure 3). α-Synuclein α-Synuclein contains a CMA recognition motif and is partially degraded in a CMA-dependent manner in isolated liver lysosomes, cell lines, neurons, and in vivo (Webb et al., 2003; Cuervo et al., 2004; Lee et al., 2004; Mak et al., 2010).”
BackgroundBuild-UPS and break-downs: metabolism impacts on proteostasis and aging
Ottens, F., Franz, A., & Hoppe, T. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00682-y · Cited by 107
Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death
Bourdenx, M., Bezard, E., & Dehay, B. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00083 · Cited by 81
Promoting Autophagic Clearance: Viable Therapeutic Targets in Alzheimer's Disease
Friedman, L. G., Qureshi, Y. H., & Yu, W. H. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0320-z · Cited by 97
Effects of Melatonin on Nervous System Aging: Neurogenesis and Neurodegeneration
Sarlak, G., Jenwitheesuk, A., Chetsawang, B., & Govitrapong, P. (2013) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13r01sr · Cited by 95
DJ-1/PARK7: A New Therapeutic Target for Neurodegenerative Disorders
Hijioka, M., Inden, M., Yanagisawa, D., & Kitamura, Y. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-01006 · Cited by 90
17-AAG Induces Cytoplasmic α-Synuclein Aggregate Clearance by Induction of Autophagy
Riedel, M., Goldbaum, O., Schwarz, L., Schmitt, S., & Richter-Landsberg, C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008753 · Cited by 87
Hou, Y.-S., Guan, J.-J., Xu, H.-D., Wu, F., Sheng, R., & Qin, Z.-H. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.00285-15 · Cited by 87
Genetic mutations and functions of PINK1
Kawajiri, S., Saiki, S., Sato, S., & Hattori, N. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.001 · Cited by 101
Molecular Insights into Parkinson's Disease
Rochet, J., Hay, B. A., & Guo, M. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00011-4 · Cited by 96
Phytochemicals Bridging Autophagy Induction and Alpha-Synuclein Degradation in Parkinsonism
Limanaqi, F., Biagioni, F., Busceti, C. L., Ryskalin, L., Polzella, M., Frati, A., & Fornai, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133274 · Cited by 92
“Conversely, exposure to autophagy inducers such as rapamycin, a gold-standard mTORC1 inhibitor, or overexpression of Beclin-1, boosts the clearance of α-syn [158,171,173].”
BackgroundSchaeffer, E., Kluge, A., Böttner, M., Zunke, F., Cossais, F., Berg, D., & Arnold, P. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.573696 · Cited by 81
“…homeostasis and pathological aggregation pathways. aSyn can be degraded via the proteasomal or via the lysosomal system, where different cathepsins have been proposed to mediate aSyn degradation (Webb et al., 2003; Sevlever et al., 2008; Cullen et al., 2009; Mak et al., 2010; Xilouri et al., 2013).”
BackgroundXu, Y., Deng, Y., & Qing, H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13234 · Cited by 97
TRIM37 defective in mulibrey nanism is a novel RING finger ubiquitin E3 ligase
Kallijärvi, J., Lahtinen, U., Hämäläinen, R. H., Lipsanen‐Nyman, M., Palvimo, J. J., & Lehesjoki, A. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.04.001 · Cited by 96
Progress in the pathogenesis and genetics of Parkinson's disease
Mizuno, Y., Hattori, N., Kubo, S., Sato, S., Nishioka, K., Hatano, T., Tomiyama, H., Funayama, M., Machida, Y., & Mochizuki, H. (2008) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2008.2273 · Cited by 107
“a-Synuclein is degraded by both autophagy and the proteasome; however, mutant forms of a-synuclein and oligomers are dependent on the autophagy–lysosome pathway for their clearance (Webb et al. 2003).”
BackgroundLi, Z., Farias, F. H. G., Dube, U., Del-Aguila, J. L., Mihindukulasuriya, K. A., Fernandez, M. V., Ibanez, L., Budde, J. P., Wang, F., Lake, A. M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02066-0 · Cited by 85
Li, B., Hu, Q., Wang, H., Man, N., Ren, H., Wen, L., Nukina, N., Fei, E., & Wang, G. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.55 · Cited by 90
Molecular pathogenesis of Parkinson's disease: update
Saiki, S., Sato, S., & Hattori, N. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301205 · Cited by 105
Dynamic structural flexibility of α-synuclein
Mor, D. E., Ugras, S. E., Daniels, M. J., & Ischiropoulos, H. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.12.018 · Cited by 99
Silica nanoparticles induce alpha-synuclein induction and aggregation in PC12-cells
Xie, H., & Wu, J. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.09.006 · Cited by 87
Mitophagy in Parkinson’s Disease: Pathogenic and Therapeutic Implications
Gao, F., Yang, J. Y., Wang, D., Li, C., Fu, Y., Wang, H., He, W., & Zhang, J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00527 · Cited by 96
Autophagy, lithium, and amyotrophic lateral sclerosis
Pasquali, L., Longone, P., Isidoro, C., Ruggieri, S., Paparelli, A., & Fornai, F. (2009) · Muscle & Nerve · doi:10.1002/mus.21423 · Cited by 83
Schwarz, L., Goldbaum, O., Bergmann, M., Probst‐Cousin, S., & Richter‐Landsberg, C. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9733-5 · Cited by 89
“α-Synuclein can be degraded either by the proteasomal machinery or by autophagy, a lysosomal pathway for degrading organelles and long-lived proteins (Webb et al. 2003; Lee et al. 2004; Vogiatzi et al. 2008; Riedel et al. 2010).”
BackgroundAutophagy in intracellular bacterial infection
Hu, W., Chan, H., Lu, L., Wong, K. T., Wong, S. H., Li, M. X., Xiao, Z. G., Cho, C. H., Gin, T., Chan, M. T. V., et al. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.07.014 · Cited by 76
Protein S-nitrosylation and oxidation contribute to protein misfolding in neurodegeneration
Nakamura, T., Oh, C.-K., Zhang, X., & Lipton, S. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.07.002 · Cited by 89
Effect of Trehalose on PC12 Cells Overexpressing Wild-Type or A53T Mutant α-synuclein
Lan, D.-M., Liu, F., Zhao, J., Chen, Y., Wu, J.-J., Ding, Z., Yue, Z., Ren, H., Jiang, Y., & Wang, J. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0823-0 · Cited by 84
“The effects of trehalose on a certain type of PC12 cells were then evaluated after its incubation for 24 h at the concentration of 10, 50 or 100 mM respectively [8, 15].”
BackgroundMethodResultInfluentialCheng, Y.-F., Zhu, G., Wang, M., Cheng, H. D., Zhou, A., Wang, N., Fang, N., Wang, X., Xiao, X., Chen, Z., et al. (2008) · Neuroscience Research · doi:10.1016/j.neures.2008.10.009 · Cited by 84
Autophagy of Mitochondria: A Promising Therapeutic Target for Neurodegenerative Disease
Kamat, P. K., Kalani, A., Kyles, P., Tyagi, S. C., & Tyagi, N. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0006-5 · Cited by 87
Pathogenesis of Parkinson's disease: emerging role of molecular chaperones
Bandopadhyay, R., & de Belleroche, J. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.11.004 · Cited by 92
α-synuclein impairs autophagosome maturation through abnormal actin stabilization
Sarkar, S., Olsen, A. L., Sygnecka, K., Lohr, K. M., & Feany, M. Β. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009359 · Cited by 85
“Since α-synuclein itself is a substrate of autophagy [24,25], promoting autophagy should reduce α-synuclein levels, including toxic phosphorylated [44,91,92], oligomeric [45], and larger α-synuclein inclusions.”
BackgroundRole of Ubiquitin–Proteasome and Autophagy-Lysosome Pathways in α-Synuclein Aggregate Clearance
Sahoo, S., Padhy, A. A., Kumari, V., & Mishra, P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02897-1 · Cited by 92
“Similarly, use of vacuolar ATPase inhibitors like bafilomycin, or oxidative stress inducers like cysteine proteases and rotenone, increased the levels of α-synuclein aggregates in SH-SY5Y cells [86, 87].”
BackgroundTóth, M. L., Simon, P., Kovács, A. L., & Vellai, T. (2007) · Journal of Cell Science · doi:10.1242/jcs.03401 · Cited by 79
“Inhibition of the autophagic-lysosomal pathway suspends the clearance of mutant huntingtin proteins (Yamada et al., 2002).”
BackgroundHarrington, A. J., Yacoubian, T. A., Slone, S. R., Caldwell, K. A., & Caldwell, G. A. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2606-11.2012 · Cited by 82
“Lysosomal targeting of misfolded and aggregated proteins for degradation, including -syn, has been shown to be largely mediated by macroautophagy and chaperone-mediated autophagy (CMA) (Webb et al., 2003; Cuervo et al., 2004).”
BackgroundAutophagy and neurodegeneration
Ventruti, A., & Cuervo, A. M. (2007) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-007-0068-5 · Cited by 96
Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H., Zweckstetter, M., Outeiro, T. F., & Braus, G. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.361865 · Cited by 81
Review: Autophagy and neurodegeneration: survival at a cost?
Cherra III, S. J., Dagda, R. K., & Chu, C. T. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01062.x · Cited by 81
The Role of ATG16 in Autophagy and The Ubiquitin Proteasome System
Xiong, Q., Li, W., Li, P., Yang, M., Wu, C., & Eichinger, L. (2018) · Cells · doi:10.3390/cells8010002 · Cited by 85
“, α-synuclein and other aggregate-prone proteins, are known to be substrates of both degradative pathways [108,109].”
BackgroundThe Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease
Titze-de-Almeida, S. S., Soto‐Sánchez, C., Fernández, E., Koprich, J. B., Brotchie, J. M., & Titze‐de‐Almeida, R. (2020) · Cells · doi:10.3390/cells9040841 · Cited by 89
Dai, B., Zhong, T., Chen, Z.-X., Chen, W., Zhang, N., Liu, X.-L., Wang, L.-Q., Chen, J., & Liang, Y. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101222 · Cited by 81
Metadata
- Authors
- Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C.
- Affiliations
- Addenbrooke's Hospital (GB)
- University of Cambridge (GB)
- Corresponding author
- Rubinsztein, David C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 27
- Pages
- 25009-25013
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2157535220
- Cited by
- 1,429
- References
- 37
- Citations by year
- 2026: 36 · 2025: 41 · 2024: 76 · 2023: 50 · 2022: 68 · 2021: 71 · 2020: 83 · 2019: 85 · 2018: 77 · 2017: 62 · 2016: 65 · 2015: 65 · 2014: 75 · 2013: 79 · 2012: 95
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6305 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Parkinson's UK
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- alpha-synuclein, Parkinson's disease, autophagy, proteasome, protein degradation, Lewy bodies, A30P mutation, A53T mutation, PC12 cells, rapamycin, autophagic vesicles, dopaminergic neurons
- MeSH terms
- Animals, Antibiotics, Antineoplastic, Autophagy, Cysteine Endopeptidases, Humans, Multienzyme Complexes, Nerve Tissue Proteins, PC12 Cells, Sirolimus, Proteasome Endopeptidase Complex, Rats, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.